'Metastatic melanoma' presentation slideshows

Pathophysiology of Melanoma: New insights into Genetics, Markers, Staging, and Treatment

Pathophysiology of Melanoma: New insights into Genetics, Markers, Staging, and Treatment. Ritu Saini, MD NY Medical Skin Solutions New York University Langone Medical Center. Epidemiology. 114,900 cases diagnosed in 2010 1/39 caucasian man, 1/58 caucasian woman

1.01k views • 58 slides

Integrins and other Adhesion receptors in Invasion and Metastasis

491 views • 37 slides

Clinical Updates Novel Agents for the Treatment of Metastatic Melanoma

Clinical Updates Novel Agents for the Treatment of Metastatic Melanoma. David F. McDermott, MD Clinical Director, Biologic Therapy Program Beth Israel Deaconess Medical Center Assistant Professor Harvard Medical School Boston, MA. Melanoma : Epidemiology 2007.

486 views • 36 slides

365 views • 31 slides

Bijoy Telivala, MD 904-438-4545 Bijoy.Telivala@csnf

Advances in Immunotherapy. Bijoy Telivala, MD 904-438-4545 Bijoy.Telivala@csnf.us. Introduction. One of the first reported events was when Dr Coley in the late 19 th century reported insertion of dead bacteria cells lead to shrinkage of sarcoma cell

325 views • 31 slides

Update treatment of melanoma

Update treatment of melanoma. R4 ???. ?????????????????. Stage III. Stage III. Prognostic factor: the numbers of LNs. Stage IV. Systemic therapy for advanced or metastatic melanoma. Ipilimumab. CTLA-4 ( cytotoxic T-lymphocyte associated antigen 4 ) a negative regulator of T cells.

426 views • 25 slides

The Changing Field of Melanoma: Ipilimumab

The Changing Field of Melanoma: Ipilimumab. The Changing Field of Melanoma: BRAF Mutations. The Changing Field of Melanoma: PD-1 and PD-L1 Antibodies. Preferred Regimens for Metastatic Melanoma. Considerations With the New Agents. First-Line Therapy for Patients With BRAF Mutation.

588 views • 24 slides

Perspectivas A ctuales del Tratamiento con Inmunoterapia en Melanoma Adyuvante

Perspectivas A ctuales del Tratamiento con Inmunoterapia en Melanoma Adyuvante. Gabriela Cinat Jefa de Oncologia de la Unidad Funcional de Melanoma y Sarcoma Instituto de Oncologia Angel H. Roffo Universidad de Buenos Aires, Argentina.

217 views • 21 slides

D.H. Clinical Pathology Conference August 21, 2015

D.H. Clinical Pathology Conference August 21, 2015. Stella Lai MD Ronald Hamilton MD. HPI.

270 views • 14 slides

TARGETED CANCER THERAPY IN 2016: WHAT THE PRACTICING PATHOLOGIST OR ONCOLOGIST NEEDS TO KNOW

TARGETED CANCER THERAPY IN 2016: WHAT THE PRACTICING PATHOLOGIST OR ONCOLOGIST NEEDS TO KNOW (SUPPLEMENTARY SLIDES). Steven J. Kussick, MD, PhD Associate Medical Director PhenoPath Laboratories May 2016. Other Hematolymphoid Disorders, FDA-Approved.

143 views • 14 slides

Kefford R et al. Proc ASCO 2010;Abstract 8503.

Phase 1/2 Study of GSK2118436, a Selective Inhibitor of Oncogenic Mutant BRAF Kinase in Patients with Metastatic Melanoma and Other Solid Tumors. Kefford R et al. Proc ASCO 2010;Abstract 8503. Introduction.

306 views • 12 slides

? ? ? ?

250 views • 11 slides

Aarkstore - Metastatic Melanoma-Global API Manufacturers

Metastatic Melanoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Melanoma. Browse full report @ http://bit.ly/18pHhFU

217 views • 11 slides

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

349 views • 10 slides

Cytokines Play an Essential Role in Intercellular Communication

203 views • 6 slides